- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Miranda Lankas | Authors
Iberdomide ± Anti-CD20 Therapy Yields Promising Responses in Relapsed/Refractory Lymphoma
December 11, 2022
Treatment with ibermodide on its own or with anti-CD20 antibodies was well tolerated and demonstrated encouraging responses among patients with relapsed or refractory lymphoma.
Chemotherapy Plus Endocrine Therapy May Confer Further Cognitive Impairment vs. Endocrine Therapy Alone for Breast Cancer Regardless of Menopausal Status
December 07, 2022
Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.
Two-Year KEYNOTE-365 Update Continues to Show Promise of Pembrolizumab Plus Abiraterone in mCRPC Naïve to Chemo
September 11, 2022
Antitumor activity and safety of pembrolizumab plus abiraterone acetate appears to be sustained in chemotherapy-naïve castration-resistant prostate cancer.
Advertisement
Advertisement